Researchers identify proteins that could help diagnose Kawasaki disease early

March 21, 2017 (Mainichi, Japan)

March 21, 2017

A research team from Yokohama City University has identified four types of protein that could be used to diagnose “Kawasaki disease” at an early stage. The discovery is important because it will hopefully lead to a reduction in heart complications that occasionally develop as a result of the illness.

Yokohama City University associate professor Yayoi Kimura and her team of fellow researchers observed that the concentration levels of four different proteins — LBP, LRG1, AGT and RBP4 — changed during the acute or early phase of Kawasaki disease.

These findings are significant because the disease is known for being difficult to diagnose during the acute stage. There are at least five prominent symptoms, such as fever, red eyes and rash. But because it takes between three to seven days for these symptoms to appear altogether, even experts hesitate to commence treatment before all the symptoms are there.

Therefore, in the future, if doctors are able to identify protein-level related changes during the acute phase of Kawasaki disease, it should facilitate an earlier diagnosis, and hence enable treatment to commence more quickly. In cases where symptoms persist for 10 days or so after onset, and are not treated, heart complications such as coronary artery disease can develop in 25 to 30 percent of patients.

Having made this discovery, Yokohama City University now intends to test a diagnostic agent in clinical trials from fiscal 2017 onward, in collaboration with a Japanese company, having already applied for an international patent. Looking ahead, Kimura is positive. “We are hoping that our findings can be used in four to five years time to make actual diagnoses.”

To read the full article, click here.

New Research

Canadian researchers bring new insights into Kawasaki disease and its consequences

January 28, 2017

(January 2017) — Kawasaki disease (KD) is the leading cause of acquired heart disease in Canadian children. While some of the approximately 500 children diagnosed annually in Canada will have no lingering effects, some will develop lifelong heart problems. Recent publications by researchers located, primarily, at The Hospital for Sick Children in Toronto (SickKids) and at Centre Hospitalier Universitaire Ste. Justine (CHU-SJ) in Montreal, are beginning to peel back some of the mysteries surrounding Kawasaki disease, helping both patients and their families.

Click to read full article: January 2017 Canadian researchers bring new insights into Kawasaki disease and its consequences

Today is Kawasaki Disease Awareness Day

Canadian researchers bring new insights into the disease and its consequences

January 26, 2017

 PRESS RELEASE:  ISSUE DATE – THURSDAY, JANUARY 26, 2017

Today is Kawasaki Disease Awareness Day

Canadian researchers bring new insights into the disease and its consequences

(Winnipeg, January 26, 2017) — Kawasaki disease (KD) is the leading cause of acquired heart disease in Canadian children.  While some of the approximately 500 children diagnosed annually in Canada will have no lingering effects, some will develop lifelong heart problems.  Recent publications by researchers located, primarily, at The Hospital for Sick Children in Toronto (SickKids) and at Centre Hospitalier Universitaire Ste. Justine (CHU-SJ) in Montreal, are beginning to peel back some of the mysteries surrounding Kawasaki disease, helping both patients and their families.

A recent publication by nurse practitioner Nita Chahal (SickKids) and her colleagues explores some of the psychosocial factors impacting the lives of children and their families when Kawasaki disease results in coronary artery aneurysms (CAA).  CAAs result in many intrusive procedures, require constant management by children and their parents, and can leave children and parents feeling uncertain about the future.  While this results in a considerable burden of struggle for families, Chahal et al. also found a “cautious optimism,” which increased where families had consistent and reliable information about their child’s health.

Newly published research by SickKids’ Dr. Brian McCrindle and colleagues re-affirms the importance of early diagnosis.  If treated within ten days of the onset of Kawasaki disease, intravenous immunoglobulin can reduce the chances of developing CAA.  The research found, however, other factors that can affect the outcome.

Dr. Rae Yeung, also at SickKids, identified regulation of calcium mobilization as fundamental to the underlying biology of Kawasaki disease leading to a unique IL-1β signature, totally changing the way we think and treat Kawasaki disease as we already have powerful medications to block IL-1β.  Her group identified a novel function for a gene, ITPKC, that controls calcium mobilization but more importantly controls the response to IVIG treatment.  Along the same theme, Dr. Yeung together with a group of international colleagues, examined genomic data from children with Kawasaki disease from around the world, including North America, Europe and Japan, identifying a form of another gene responsible for the regulation of calcium ion levels through channels in the cell membrane, SLC8A1, that is associated with both Kawasaki disease and CAAs.

In Montreal, a team led by Dr. Nagib Dahdah and located principally at CHU-Ste-Justine examines important clinical questions in patient populations in Canada based on novel insights from the Kawasaki disease community more broadly.  They have shown, for example, that the presence of a form of natriuretic peptide (an inflammatory marker) can add to the diagnostic criteria set out by the American Heart Association for KD and can be especially helpful in the diagnosis of incomplete KD.  In the case of KD patients with CAAs, Dahdah and his team found that coronary artery bypass grafting (CABG)—often multivessel–was preferable to percutaneous coronary intervention (PCI).

Drs. Dahdah, Chahal, McCrindle and Yeung have also been authors of several other papers on Kawasaki disease published in the past year.   See the list of publications below, representing just the past year.

Kawasaki Disease Canada, a registered charity, focuses on increasing awareness to enable early diagnosis, supporting families affected by KD, and supporting new research.  Today, Kawasaki Disease Canada announces its second Student Research Award, with a deadline for applications of February 22.  The Inaugural Student Research Award winner was Mathew Mathew, also at SickKids.  Mathew’s research involves constructing models of the hearts of KD patients with large coronary aneurysms and using computers to see how the blood flows through them.  This is expected to help determine how the location and shape of the aneurysm affects the chances of forming blood clots.

Early diagnosis is critical in treating Kawasaki disease but the symptoms aren’t always straightforward. Typical Kawasaki disease presents as a prolonged fever lasting five days or more with at least four other symptoms, including:

  • a rash
  • bloodshot eyes
  • bright red, swollen, cracked lips
  • “strawberry tongue”
  • swollen hands and feet
  • redness of the palms and soles of the feet
  • swollen lymph nodes in the neck

However, Kawasaki Disease Canada encourages parents to ask their doctor about Kawasaki disease when a prolonged fever is accompanied by any two of the above symptoms.

 

About Kawasaki Disease Awareness Day

January 26 is the anniversary of the day in 1961 that Japanese doctor Tomisaku Kawasaki began to recognize a cluster of symptoms that led to the classification “Kawasaki disease”, which is also known as “KD”.  Kawasaki Disease Canada is posting 26 days of information about KD on its Facebook page, “Kawasaki Disease Canada”, promoting a #ShowUsYourHeart social media awareness campaign, and encouraging supporters to wear red on January 26, to give blood, and/or to make a donation via its website, kdcanada.org, or CanadaHelps.


 

About Kawasaki Disease Canada

Kawasaki Disease Canada is a national non-profit and registered charity with a mission to promote awareness and education about Kawasaki disease, support individuals and family members affected by the disease, and advance research into the disease and its consequences.  For more information, visit kdcanada.org.

###

 

For more information contact:

About Kawasaki Disease Canada:

Elizabeth Heald

President, Kawasaki Disease Canada

226-218-5100

elizabeth@kdcanada.org

 

About Kawasaki disease research at SickKids Hospital:

Dr. Brian McCrindle: 416-432-3001

Dr. Rae Yeung:  416-813-8964 or rae.yeung@sickkids.ca

 

About Kawasaki disease research at CHU Ste-Justine (English / French):

Dr. Nagib Dahdah: 514-345-4931 (ext: 4573) or info@BoBeauCoeur.org

 

About the Student Research Award:

Dr. Susan Heald

Chair, Research Committee, Kawasaki Disease Canada

susan@kdcanada.org

Or see the website, kdcanada.org/research

 


 

Publications mentioned:

Chahal N, Jelen A, Rush J, Manlhiot C, Boydell KM, Sananes R, McCrindle BW. Kawasaki Disease with Coronary Artery Aneurysms: Psychosocial Impact on Parents and Children.  Journal of Pediatric Health Care.

Downie ML, Manlhiot C, Collins TH, Chahal N, Yeung RSM, McCrindle, B. Factors associated with development of coronary artery aneurysms after Kawasaki disease are similar for those treated promptly and those with delayed or no treatment. International Journal of Cardiology, In Press.  Published online: January 7, 2017

Downie ML, Manlhiot C, Latino GA, Collins TH, Chahal N, Yeung RSM, McCrindle BW. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.  J Pediatr. 2016 Dec; 179:124-130.

Alphonse MP, Duong TT, Shumitzu C, Hoang TL, McCrindle BW, Franco A, Schurmans S, Philpott DJ, Hibberd ML, Burns J, Kuijpers TW, Yeung RSM. Inositol-Triphosphate 3-Kinase C mediates inflammasome activation and treatment response in Kawasaki disease. Journal of Immunology 2016: 197(9): 3481-3489.

Shimizu C, Eleftherohorinou H, Wright VJ, Kim J, Alphonse MP, Perry JC, Cimaz R, Burgner D, Dahdah N, Hoang LT, Khor CC, Salgado A, Tremoulet AH, Davila S, Kuijpers TW, Hibberd ML, Johnson TA, Takahashi A, Tsunoda T, Kubo M, Tanaka T, Onouchi Y, Yeung RSM, Coin LJM, Levin M, Burns JC on behalf of the International Kawasaki Disease Genetic Consortium. Genetic variation in the SLC8A1 calcium signaling pathway is associated with susceptibility to Kawasaki disease and coronary artery abnormalities.  Circulation Cardiovascular Genetics 2016: 9(6): 559-568.

Dionne A, Bakloul M, Manlhiot C, McCrindle BW, Hosking M, Houde C, Pepelassis D, Dahdah N. Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention after Kawasaki Disease: The Pediatric Canadian Series. Pediatric Cardiology. 2016 Sep 23

Dionne A, Meloche-Dumas L, Desjardins L, Turgeon J, Saint-Cyr C, Autmizguine J, Spigelblatt L, Fournier A, Dahdah N. N-terminal pro-B-type natriuretic peptide diagnostic algorithm versus American Heart Association algorithm for Kawasaki disease. Pediatrics International. 2016 Sep 2. doi: 10.1111/ped.13154.